The Role of Epiretinal Membrane on Treatment of Neovascular Age-Related Macular Degeneration with Intravitreal Bevacizumab

Purpose. To determine the effect of epiretinal membranes (ERM) on the treatment response and the number of intravitreal bevacizumab injections (IVB) in patients with neovascular age-related macular degeneration (nAMD). Methods. A retrospective chart review was performed on 63 eyes of 63 patients. Th...

Full description

Bibliographic Details
Published in:	The Scientific World Journal
Main Authors:	Zeynep Alkin, Abdullah Ozkaya, Ozen Ayranci Osmanbasoglu, Alper Agca, Yalcin Karakucuk, Ahmet Taylan Yazici, Ahmet Demirok
Format:	Article
Language:	English
Published:	Wiley 2013-01-01
Online Access:	http://dx.doi.org/10.1155/2013/958724

Similar Items

Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?
by: Abdullah Ozkaya, et al.
Published: (2013-01-01)

Diurnal Choroidal Thickness Changes in Normal Eyes of Turkish People Measured by Spectral Domain Optical Coherence Tomography
by: Ozen Ayrancı Osmanbasoglu, et al.
Published: (2013-01-01)

Intravitreal bevacizumab for neovascular age-related macular degeneration
by: Junn R. Pajarillo, MD, et al.
Published: (2009-12-01)

Efficacy of Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration
by: Ariunzaya Altankhuyag, et al.
Published: (2022-12-01)

ROLE OF INTRAVITREAL BEVACIZUMAB INJECTION FOR MANAGEMENT OF NEOVASCULAR AGE RELATED MACULAR DEGENERATION
by: Neha K. Desai, et al.
Published: (2016-06-01)

Macular Hole following Intravitreal Bevacizumab Injection in Choroidal Neovascularization Caused by Age-Related Macular Degeneration
by: Elad Moisseiev, et al.
Published: (2010-08-01)

Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
by: Kai Fang, et al.
Published: (2013-01-01)

Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab
by: Deepali R Damkondwar, et al.
Published: (2022-01-01)

Intravitreal Ranibizumab Therapy in Wet Type Macular Degeneration
by: Hüseyin Dündar, et al.
Published: (2014-10-01)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
by: David R. Griffin, et al.
Published: (2014-01-01)

Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
by: Tuğba Aydoğan, et al.
Published: (2016-12-01)

Trabeculectomy with concurrent intravitreal bevacizumab in neovascular glaucoma
by: Sardar M Khan, et al.
Published: (2024-01-01)

Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
by: P William Conrad, et al.
Published: (2008-06-01)

The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects
by: Cengiz Alagöz, et al.
Published: (2016-10-01)

Photodynamic therapy and intravitreal bevacizumab with versus without triamcinolone for neovascular age-related macular degeneration; a randomized clinical trial
by: Niloofar Piri, et al.
Published: (2014-01-01)

Choroidal Response to Intravitreal Bevacizumab Injections in Treatment-Naïve Macular Neovascularization Secondary to Chronic Central Serous Chorioretinopathy
by: David Rabinovitch, et al.
Published: (2024-12-01)

Intravitreal Ranibizumab for Diabetic Macular Edema Patients with Good Baseline Visual Acuity: A Real-Life Study
by: Abdullah Ozkaya, et al.
Published: (2017-10-01)

Comparison of two different treatment regimens’ efficacy in neovascular age-related macular degeneration in Turkish population—based on real life data-Bosphorus RWE Study Group
by: Burak Erden, et al.
Published: (2020-01-01)

Intravitreal bevacizumab for management of choroidal osteoma without choroidal neovascularization
by: Farhad Fazel Najafabadi, et al.
Published: (2015-01-01)

Intravitreal bevacizumab and diabetic papillopathy with macular edema
by: Beuy Joob, et al.
Published: (2012-01-01)

Real-World Evaluation of the Effectiveness of Intravitreal Bevacizumab Injection for Neovascular Age-Related Macular Degeneration at Cipto Mangunkusumo National Referral Hospital
by: Gitalisa Andayani Adriono, et al.
Published: (2025-10-01)

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
by: Hang A, et al.
Published: (2024-12-01)

Comment on “Intravitreal conbercept injection for neovascular age-related macular degeneration”
by: Dan Călugăru, et al.
Published: (2020-02-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

COMPARISON OF INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE WITH INTRAVITREAL BEVACIZUMAB ALONE IN MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
by: Usman Attique, et al.
Published: (2021-03-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
by: Emilia Maggio, et al.
Published: (2022-09-01)

Intravitreal Bevacizumab Alone Versus Combined Bevacizumab and Macular Grid Laser Photocoagulation in Diffuse Diabetic Macular Oedema
by: Fawaz Al Sarireh, et al.
Published: (2020-11-01)

Effect of Preoperative Intravitreal Bevacizumab on the Surgical Outcome of Neovascular Glaucoma at Different Stages
by: Junki Kwon, et al.
Published: (2017-01-01)

Pre-trabeculectomy intravitreal injections of Bevacizumab for treating neovascular glaucoma in diabetic patients
by: Marjanović Ivan, et al.
Published: (2020-01-01)

Occult retinal neovascularization following intravitreal bevacizumab and laser treatment for retinopathy of prematurity
by: Wei Loon Ng, et al.
Published: (2024-05-01)

Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
by: Kubota-Taniai M, et al.
Published: (2011-07-01)

The Effects of Intravitreal Bevacizumab in Infectious and Noninfectious Uveitic Macular Edema
by: Hassan Al-Dhibi, et al.
Published: (2014-01-01)

The effect of intravitreal brolucizumab on choroidal thickness in patients with neovascular age-related macular degeneration
by: Ki Woong Bae, et al.
Published: (2022-11-01)

Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors
by: Fabiana Mallone, et al.
Published: (2021-10-01)

Intravitreal bevacizumab for iatrogenic choroidal neovascular membrane following vitreoretinal surgery for retinal detachment
by: Ramya Appanraj, et al.
Published: (2020-01-01)

Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
by: Hidetaka Matsumoto, et al.
Published: (2023-02-01)

Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema
by: Karen Joyce G, Castro, MD, et al.
Published: (2014-12-01)

Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration
by: Gebran Khneizer, et al.
Published: (2017-07-01)

The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation
by: Ristić Dragana, et al.
Published: (2013-01-01)